‘Under-the-radar’ companies could become hot acquisition targets in 2018
Nearly a dozen companies were identified in a report as potentially attractive for buyouts by larger firms. Japanese companies could be big players.
Nearly a dozen companies were identified in a report as potentially attractive for buyouts by larger firms. Japanese companies could be big players.
Deals and acquisitions, filling in pipeline gaps, externalizing assets that are no longer a good fit. What really goes on when pharma companies restructure their R&D approach?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
At the J.P. Morgan Healthcare Conference this week some of the biggest names in healthcare gathered to discuss the state of the biopharmaceuticals sector. Amidst all of the commotion, some executives took a moment to tell CNBC‘s Meg Tirrell which CEO (in any industry) they’d most like to trade places with if given the chance. […]